Brusatol, a Nrf2 Inhibitor Targets STAT3 Signaling Cascade in Head and Neck Squamous Cell Carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Signaling

Background:

• Signal transducer and activator of transcription 3 (STAT3) is a critical transcription factor involved in oncogenesis.
• Aberrant STAT3 activation is prevalent in various cancers, including head and neck squamous cell carcinoma (HNSCC).

Purpose of the Study:

• To investigate brusatol (BT) as a potential inhibitor of the STAT3 signaling pathway in HNSCC cells.
• To elucidate the molecular mechanisms underlying BT's anti-cancer effects in HNSCC.

Main Methods:

• Cell-based assays were employed to assess BT's effects on HNSCC cell viability and STAT3 signaling.
• Western blotting and RT-qPCR were used to evaluate protein and mRNA expression levels of key signaling molecules and apoptosis markers.

Main Results:

• Brusatol treatment induced cytotoxicity and abrogated STAT3 activation, including upstream kinases JAK1, JAK2, and Src.
• BT reduced nuclear STAT3 levels and DNA binding, increased apoptosis markers (annexin-V, cleaved caspase-3, cleaved PARP), and downregulated anti-apoptotic proteins (Bcl-2, Bcl-xl, survivin).

Conclusions:

• Brusatol demonstrates significant potential as an inhibitor of the STAT3 signaling pathway in HNSCC.
• BT exhibits anti-cancer properties by inducing apoptosis and reducing the expression of pro-survival proteins in HNSCC cells.